Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade

Boehringer Ingelheim

Status: Completed

Conditions: Prostatic Hyperplasia

Treatments: Drug: alpha-adrenergic blocker

Study type: Observational

Funder types: Industry

Identifiers

NCT02244307

527.28

Details and patient eligibility

About

The primary objective of this observational study was the assessment of prognosis factors for having recourse to prostatic surgery in patients with BPH who were administered class-1 alpha blockers. The secondary objectives were the assessment of the time from alpha-adrenergic blockade treatment initiation to surgery and the evolution of patients during the study.

Enrollment: 4,561 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any patient with BPH for whom alpha-blocker treatment is indicated
• Patients who are already on class-1 alpha-blockers can only participate in the study if all information required is known and/or available

Exclusion criteria

• Patient's follow-up not possible
• Patients participating in another study
• History of BPH surgery
• Prostate cancer

Trial design

4,561 participants in 1 patient group

Patients with BPH treated with alpha-andrenergic blockade

Treatment:

Drug: alpha-adrenergic blocker